KAZIA MARKS DIPG AWARENESS DAY; NEW PRECLINICAL DATA IN DIPG TO BE PRESENTED AT ISPNO CONFERENCE

Rhea-AI Summary

Kazia Therapeutics Limited (NASDAQ: KZIA) acknowledges 'DIPG Awareness Day' on May 17, 2022, highlighting the urgent need for increased awareness and research funding for childhood brain cancer, especially diffuse intrinsic pontine glioma (DIPG). This type of cancer has no FDA-approved treatment and a median survival of 9-11 months. Kazia's investigational drug, paxalisib, is under a phase II study for DIPG, with data expected in 2023. New preclinical data will be presented at the ISPNO Conference in June 2022, emphasizing the potential of paxalisib in offering hope to affected families.

Positive

• Kazia's paxalisib is currently in a phase II study for DIPG, with anticipated data in 2023.
• Promising preclinical data on paxalisib will be presented at the ISPNO Conference in June 2022.

Negative

• DIPG has no FDA-approved therapy, indicating a high unmet medical need.
• The median survival for DIPG patients is only 9-11 months post-diagnosis.

SYDNEY, May 17, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a late-stage, oncology-focused drug development company, marks 'DIPG Awareness Day' by recognizing the tireless work of global researchers in this disease, and by calling for an increased focus on childhood brain cancer among policymakers.

Brain tumours represent the second most common group of cancers in children worldwide, after leukemia, but are the most common cause of cancer death. Around 10-15% of childhood brain cancers are diffuse midline gliomas (DMGs), a group that includes diffuse intrinsic pontine glioma (DIPG).

DIPG most commonly affects children between four and eleven years of age. There is currently no FDA-approved therapy for the disease, and median survival is just 9 – 11 months from diagnosis.

Kazia's paxalisib is the subject on an ongoing phase II study in DIPG and DMGs (NCT05009992), sponsored by the Pacific Pediatric Neuro-Oncology Consortium (PNOC). Data from the study is anticipated in CY2023.

New Data to be Presented at ISPNO Conference

The PNOC phase II study has been substantially informed by work undertaken at the Hunter Medical Research Institute in Newcastle, Australia, by Associate Professor Matt Dun and colleagues. Dr Dun is one of the leading researchers in this disease.

Dr Dun will be presenting new preclinical data describing the activity of paxalisib in DIPG at the upcoming 20^th International Symposium on Pediatric Neuro-Oncology (ISPNO), which will be held in Hamburg, Germany, from 11 to 12 June 2022. Dr Dun's presentation will specifically cover the combination of paxalisib with ONC201 (Chimerix, Inc).

Dr Dun commented, "Thirty years ago, children diagnosed with leukemia only had a 20-30% chance of survival. Thanks to advances in medicine and a wealth of scientific research, that has now increased to over 90%. This is the paradigm we want to mirror with DIPG and I am pleased to report we are currently seeing some very promising results with our research. We are working tirelessly to progress the human clinical trials with the aim of being able to offer new hope to those families with a DIPG diagnosis."

Upcoming Analyst Presentation

Kazia CEO, Dr James Garner, will participate in an upcoming analyst discussion on childhood brain cancer, led by Dr Naureen Quibria, Senior Biotech Analyst at Maxim Group. The panel discussion will also include Dr Josh Allen, Chief Medical Officer of Chimerix, Inc, and Dr Sabine Mueller, lead investigator on the PNOC phase II study of paxalisib and ONC201 in DIPG.

The webinar is scheduled for 9am, ET, on Thursday 19 May 2022 and interested parties may register to attend the webinar via the following link:-

https://m-vest.com/events/pediatric-brain-cancer-05192022

DIPG Factsheet Launched

To recognize DIPG Awareness Day, and to encourage awareness and discussion of the disease, Kazia Therapeutics has supported the development of a fact sheet, which can be downloaded from the Kazia website using the following link:-

https://www.kaziatherapeutics.com/site/PDF/c4f1dc99-6874-49ea-af10-cfa3a5a8f39b/KaziaDIPGFactSheet 

View original content to download multimedia:https://www.prnewswire.com/news-releases/kazia-marks-dipg-awareness-day-new-preclinical-data-in-dipg-to-be-presented-at-ispno-conference-301547724.html

SOURCE Kazia Therapeutics Limited

FAQ

What is Kazia Therapeutics' focus regarding DIPG?

Kazia Therapeutics focuses on developing paxalisib for DIPG treatment, currently in a phase II study.

When will data from Kazia's DIPG study be available?

Data from the ongoing phase II study of paxalisib in DIPG is expected in 2023.

What is the significance of DIPG Awareness Day for Kazia?

DIPG Awareness Day emphasizes the need for increased awareness and research funding for childhood brain cancer, which Kazia supports.

What is the survival rate for patients diagnosed with DIPG?

The median survival for DIPG patients is just 9-11 months from diagnosis.

Where will the new preclinical data on paxalisib be presented?

The new preclinical data will be presented at the ISPNO Conference in Hamburg, Germany, in June 2022.